Treatment of Basal Cell Carcinomas With Methyl Aminolevulinate and Daylight
Phase 2
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Both
Photodynamic Therapy, Basal Cell Carcinomas
Both
Photodynamic Therapy, Basal Cell Carcinomas
Trial Information
Treatment of Basal Cell Carcinomas With Methyl Aminolevulinate and Daylight
Inclusion Criteria:
- superficial BCC
Exclusion Criteria:
- Immunosuppression
Type of Study:
Interventional
Study Design:
N/A
Outcome Measure:
complete disappearance of the BCC
Authority:
Denmark: Danish Medicines Agency
Study ID:
2010-024517-31
NCT ID:
NCT01349361
Start Date:
March 2011
Completion Date:
Related Keywords:
- Photodynamic Therapy
- Basal Cell Carcinomas
- Carcinoma
- Carcinoma, Basal Cell
Name | Location |
|---|
